Sino Biopharmaceutical Limited: Neoplasms trials

The registry lists 50 Neoplasms studies with Sino Biopharmaceutical Limited as lead sponsor. 14 are open to participants now and 0 have results posted.

Phase 1 46Phase 2 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid TumorsNot yet recruitingNCT07694765Phase 1/2
• A Study of LM-350 in Subjects With Advanced Solid TumoursRecruitingNCT07112222Phase 1/2
• A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid MalignanciesRecruitingNCT07011186Phase 1/2
• A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid TumoursNot yet recruitingNCT06873854Phase 2
• Study of LM-299 in Subjects Advanced Malignant TumorsRecruitingNCT06650566Phase 1/2
• A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant TumorsNot yet recruitingNCT06649656Phase 1
• A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic MalignancyNot yet recruitingNCT06211751Phase 1
• Clinical Trial of TQB2922 for Injection in Patients With Advanced CancersRecruitingNCT06188624Phase 1
• A Study to Evaluate Drug-Drug Interaction of TQB3909 TabletsNot yet recruitingNCT06165822Phase 1
• A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.RecruitingNCT05970016Phase 1/2
• TQB2223 Injection in Combination With Penpulimab in Patients With Advanced CancersRecruitingNCT05894421Phase 1
• Clinical Trial Evaluating the Safety of the TQB2103 for InjectionRecruitingNCT05867563Phase 1
• A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant TumorsRecruitingNCT05615974Phase 1/2
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant TumorsRecruitingNCT04805060Phase 1
• A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant CancerCompletedNCT06344351Phase 1
• TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.TerminatedNCT06297642Phase 1
• A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid TumorsCompletedNCT06172309Phase 1
• A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant CancerWithdrawnNCT06165809Phase 1
• A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid TumorsActive, not recruitingNCT06116240Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid TumorsStatus unknownNCT05818917Phase 1
• Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid TumorsStatus unknownNCT05645315Phase 1/2
• Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid TumorsStatus unknownNCT05416359Phase 1
• Clinical Trial of the TQB2930 Injection in Patients With Advanced CancersStatus unknownNCT05380882Phase 1
• Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced CancersActive, not recruitingNCT05333276Phase 1
• Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid TumoursTerminatedNCT05255484Phase 1/2
• Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant TumorsStatus unknownNCT05213767Phase 1
• Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant TumorsStatus unknownNCT05198505Phase 1
• Clinical Trial of the TQB2928 Injection in Patients With Advanced CancersStatus unknownNCT05192512Phase 1
• Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid TumorsCompletedNCT05188664Phase 1/2
• A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant TumorsStatus unknownNCT05110807Phase 1
• A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant TumorsStatus unknownNCT05046847Phase 1
• A Clinical Study of TQB3824 in Subjects With Advanced CancerStatus unknownNCT05028218Phase 1
• A Study of TQB3820 in Patients With Hematological MalignanciesStatus unknownNCT05020639Phase 1
• Study of LM-102 in Patients With Advance Solid TumorsTerminatedNCT05008445Phase 1/2
• A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant TumorsStatus unknownNCT04975204Phase 1
• Phase 1 Trial of the TQB2928 Injection in Patients With Advanced CancersStatus unknownNCT04854681Phase 1
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid TumorsStatus unknownNCT04623892Phase 1
• A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological MalignanciesStatus unknownNCT04412577Phase 1
• A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant TumorStatus unknownNCT04412564Phase 2
• A Study of TQB3455 Tablets in Subjects With Advanced MalignanciesStatus unknownNCT04340427Phase 1
• A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid TumorStatus unknownNCT04291248Phase 2
• A Study of Anlotinib in Subjects With Advanced MalignancyCompletedNCT04216082Phase 2
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant TumorsStatus unknownNCT04128085Phase 1
• Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid TumorsStatus unknownNCT03897283Phase 1
• A Phase I Study of TQ-B3139 on Tolerance and PharmacokineticsStatus unknownNCT03099330Phase 1
• A Phase I Study of TQ-B3101 on Tolerance and PharmacokineticsStatus unknownNCT03019276Phase 1
• A Phase I Study of TQ-B3234 on Tolerance and PharmacokineticsStatus unknownNCT02996838Phase 1
• A Phase I Study of TQ-B3395 on Tolerance and PharmacokineticsTerminatedNCT02944864Phase 1
• A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer PatientsCompletedNCT02825563Phase 1
• A Study of AL2846 on Tolerance and PharmacokineticsStatus unknownNCT02779699Phase 1